Inclisiran manufacturers

Filters

Filters

Filters , active

Country of origin : Netherlands

inclisiran

Injection, pre-filled syringe 284 mg

Dossier type
US CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
FDA, EU GMP
Manufacturer #276
This company is a global manufacturer and distributor of high-quality generic medicines, with a mission to make these medicines accessible to patients worldwide. It operates in several regions, including Europe and Latin America, and emphasizes strong partnerships within the pharmaceutical industry to expand its reach. The company is committed to sustainability and transparency, following Environmental, Social, and Governance (ESG) principles. They regularly engage in major industry events, highlighting their dedication to networking and maintaining a leading position in the market for generic medications.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

About inclisiran

Inclisiran manufacturers are currently limited to the originator, Novartis, which sells it as Leqvio. Inclisiran is a small interfering RNA (siRNA) that lowers LDL cholesterol by silencing the PCSK9 gene in the liver. It is injected under the skin twice a year after two initial doses, which makes it one of the least frequently dosed cholesterol treatments. No generic is approved. Companies interested in inclisiran can explore future generic development or oligonucleotide manufacturing partnerships.

Inclisiran key facts

Property

Inclisiran

INN

Inclisiran (as sodium)

Molecule type

Chemically modified double-stranded siRNA conjugated to GalNAc (liver targeting)

ATC code

C10AX16

Drug class

PCSK9 siRNA; lipid-lowering agent

Brand name

Leqvio

Originator

Developed with Alnylam technology by The Medicines Company; acquired by Novartis in 2020

Dosage form and strength

Solution for subcutaneous injection, 284 mg in prefilled syringe

Dose

284 mg at day 0, month 3, then every 6 months

Indications

Primary hypercholesterolaemia and mixed dyslipidaemia, to lower LDL cholesterol, with diet and other lipid-lowering therapy as appropriate

First approval

EU, December 2020

US approval

FDA, December 2021

Generic status

None approved

Inclisiran manufacturers and licensing history

Inclisiran was developed by The Medicines Company using Alnylam's RNA interference technology. Novartis acquired The Medicines Company in January 2020. The EU approved Leqvio in December 2020, and the FDA in December 2021.

Inclisiran works by a different mechanism from statins and PCSK9 antibodies. Because it is given only twice a year by a healthcare professional, it can help patients who struggle with daily tablets or frequent injections. Novartis has since broadened its use and is running cardiovascular outcomes studies.

No generic inclisiran is approved. Generic developers would need oligonucleotide synthesis and GalNAc conjugation capability. Buyers should confirm manufacturing capability, impurity control and freedom to operate.

Inclisiran dosage forms and dossier types

Inclisiran is supplied as a 284 mg solution for subcutaneous injection in a single-dose prefilled syringe.

Form

Strengths

Typical dossier

Notes

Inclisiran injection

284 mg/1.5 ml prefilled syringe

Future US ANDA; EU CTD

Reference Leqvio

Inclisiran drug substance

Bulk

Future DMF

Oligonucleotide synthesis and GalNAc conjugation

Target market

Dossier format

Key requirement

United States

Future ANDA

Patents and exclusivities

European Union

Future EU CTD

Data protection and SPC expiry

Other markets

CTD

Check local patents

Inclisiran regulatory and patent status

The EU approved inclisiran in December 2020, and the FDA in December 2021. It is protected by patents and regulatory exclusivities, and no generic is approved. Check national patent registers before planning development.

Inclisiran mechanism of action and therapeutic use

Inclisiran enters liver cells through the GalNAc receptor and uses RNA interference to destroy the messenger RNA for PCSK9. With less PCSK9, more LDL receptors stay on the liver cell surface and remove LDL cholesterol from the blood. Inclisiran is injected by a healthcare professional at the start, after 3 months and then every 6 months, usually alongside a statin.

Inclisiran licensing and sourcing

Inclisiran is currently available only from Novartis. Companies interested in this molecule usually prepare future generic dossiers or oligonucleotide manufacturing partnerships. Current offers and supplier contacts are listed among the inclisiran manufacturers on Pipelinepharma.

Frequently asked questions about inclisiran

Who manufactures inclisiran? Novartis is the only manufacturer and sells inclisiran as Leqvio.

How often is inclisiran given? Inclisiran is injected at the start, after 3 months and then every 6 months.

What is inclisiran used for? Inclisiran is used to lower LDL cholesterol in adults with hypercholesterolaemia or mixed dyslipidaemia.

Is there a generic version of inclisiran? No. No generic inclisiran is approved.

How is inclisiran different from PCSK9 antibodies? PCSK9 antibodies, such as evolocumab, block PCSK9 in the blood every 2–4 weeks. Inclisiran stops PCSK9 being made in the liver and is given twice a year.

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.